(Q36052831)

11 August 2017

1 reference

title

Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications (English)

1 reference

11 August 2017

1 reference

1 reference

1 reference

1 reference

1 reference

1 reference

5

Jean-Marc Tréluyer

0 references

author name string

Frederike Lentz

1

1 reference

11 August 2017

Agnès Tran

2

1 reference

11 August 2017

Elisabeth Rey

3

1 reference

11 August 2017

Gérard Pons

4

1 reference

11 August 2017

Jean-Marc Tréluyer

5

1 reference

11 August 2017

1 January 2005

1 reference

Molecular Diagnosis and Therapy

11 August 2017

1 reference

11 August 2017

5

1 reference

11 August 2017

1

1 reference

11 August 2017

21-33

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.tpj.6500281

11 August 2017

0 references

cites work

One year effectiveness of an individualised smoking cessation intervention at the workplace: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500281

Cellular mechanisms of nicotine addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500281

Nicotine as a modulator of behavior: beyond the inverted U.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500281

Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500281

The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500281

Case-control study of the D2 dopamine receptor gene and smoking status in lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500281

The genetic basis for smoking behavior: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500281

Current pharmacological treatments for nicotine dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500281

In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500281

Dopaminergic mediation of the discriminative stimulus effects of bupropion in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500281

Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: a randomized placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500281

A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500281

Bupropion SR and smoking cessation in actual practice: methods for recruitment, screening, and exclusion for a field trial in a managed-care setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500281

Effectiveness of bupropion sustained release for smoking cessation in a health care setting: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500281

Comment on "The public health implications of smoking-induced decreased serum and red blood cell folate levels".

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500281

Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500281

Bupropion for smoking cessation : predictors of successful outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500281

Bupropion SR and counseling for smoking cessation in actual practice: predictors of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500281

Heterogeneity in 12-month outcome among female and male smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500281

Effects of gender on relapse prevention in smokers treated with bupropion SR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500281

DRD2 allele frequencies and linkage disequilibria, including the -141CIns/Del promoter polymorphism, in European-American, African-American, and Japanese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500281

Assessing linkage disequilibrium in a complex genetic system. I. Overall deviation from random association.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500281

Single-dose pharmacokinetics of bupropion in adolescents: effects of smoking status and gender

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500281

Inhibition of cytochrome P450 2B6 activity by hormone replacement therapy and oral contraceptive as measured by bupropion hydroxylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500281

Gender differences in dopaminergic function in striatum and nucleus accumbens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500281

Biological basis of sex differences in drug abuse: preclinical and clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500281

Striatal dopamine transporters and cognitive functioning in healthy men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500281

Sex differences in [123I]beta-CIT SPECT measures of dopamine and serotonin transporter availability in healthy smokers and nonsmokers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500281

Pharmacogenetic investigation of smoking cessation treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500281

Genetic clues to the molecular basis of tobacco addiction and progress towards personalized therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500281

Pharmacogenomics: translating functional genomics into rational therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500281

Treatment non-adherence in affective disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500281

The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500281

The need for dissemination of evidence-based results from research on nicotine and tobacco

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500281

DNA by mail: an inexpensive and noninvasive method for collecting DNA samples from widely dispersed populations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500281

Allelic association of human dopamine D2 receptor gene in alcoholism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500281

Identification of the nicotinic receptor subtypes expressed on dopaminergic terminals in the rat striatum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500281

7 January 2021

D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500281

7 January 2021

The dopamine D2 receptor (DRD2) gene: a genetic risk factor in smoking.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500281

7 January 2021

Family-based study of the association of the dopamine D2 receptor gene (DRD2) with habitual smoking

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500281

7 January 2021

Lack of association between the dopamine D2 receptor gene allele DRD2*A1 and cigarette smoking in a United Kingdom population.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500281

7 January 2021

A comparison of sustained-release bupropion and placebo for smoking cessation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500281

7 January 2021

Estrous cycle-dependent variation in amphetamine-induced behaviors and striatal dopamine release assessed with microdialysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500281

7 January 2021

Testing drug response in the presence of genetic information: sampling issues for clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500281

7 January 2021

Biochemical verification of tobacco use and cessation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500281

7 January 2021

Biochemical validation of smoking status: pros, cons, and data from four low-intensity intervention trials.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500281

7 January 2021

Self-help quit smoking interventions: effects of self-help materials, social support instructions, and telephone counseling.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500281

7 January 2021

The validity of self-reported smoking: a review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500281

7 January 2021

Nonadherence with mood stabilizers: prevalence and predictors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500281

7 January 2021

Duration of therapy and health care costs of fluoxetine, paroxetine, and sertraline in 6 health plans.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500281

7 January 2021

Mutation detection by TaqMan-allele specific amplification: application to molecular diagnosis of glycogen storage disease type Ia and medium-chain acyl-CoA dehydrogenase deficiency

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500281

7 January 2021

Identifiers

DOI

10.1038/SJ.TPJ.6500281

1 reference

11 August 2017

1 reference